Takara Bio Inc. ( (JP:4974) ) has shared an update.
Takara Bio Inc. announced a downward revision of its financial forecasts for the fiscal year ending March 31, 2025, due to ongoing inflation in the U.S. and Europe, as well as economic recession in China. These conditions have led to deteriorating market conditions and intensified price competition, negatively impacting sales and profits in their Reagents and Instruments and CDMO businesses. Despite efforts to reduce expenses, the company expects lower net sales and profitability compared to previous forecasts.
More about Takara Bio Inc.
Takara Bio Inc. operates in the life sciences industry, focusing on the development and sale of research reagents, scientific instruments, and contract development and manufacturing organization (CDMO) services. The company primarily targets the global market, addressing challenges and advancing innovations in life science research and development.
YTD Price Performance: -4.29%
Average Trading Volume: 167,496
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: Yen121B
For a thorough assessment of 4974 stock, go to TipRanks’ Stock Analysis page.